Three Cases of Ectopic Adrenocorticotropic Hormone Syndrome Due to Medullary Thyroid Carcinoma Abstract #1266

Introduction: Сushing's syndrome (CS) in medullar thyroid carcinoma (MTC) is rare. Among patients with MTC 0,7 % developed ectopic ACTH-syndrome (EAS). EAS due to MTS occurs in 2,2-8% of cases.
Aim(s): We report 3 cases of MTC with EAS.
Materials and methods: It was 2 men (16 and 21 years old) and 1 woman 40 years old.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Iya Voronkova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#201 Comparison of 18F-DOPA, 68Ga-Somatostatin Analogues and 18F-FDG PET-CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Various PET tracers have been proposed for detection of recurrent disease in medullary thyroid carcinoma (MTC). No data have been reported comparing 18F-DOPA and 68Ga-somatostin analogues (SA) in MTC.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#276 Mammalian Target of Rapamycin Pathway Activation is Associated with RET Mutation Status in Medullary Thyroid Carcinoma
Introduction: The genetic pathways involved in medullary thyroid carcinoma (MTC), except for RET mutations, are largely unknown, as well as the detailed expression mapping of intracellular signalling transducers.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Marco Volante
#333 Sporadic Hypercalcitoninemia: Thyroid Medullary carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists’ Effect?
Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists’ stimulated C-cell hyperplasia and tumors in rodents, but not in humans. Calcitonin also increased in autoimmune thyroid disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Raluca A. Trifanescu
#351 Comparison of 68Ga-Somatostatin Analogues, 18F-DOPA and 18F-FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Early detection of recurrences is a crucial step in the management of patients (pts) with medullary thyroid carcinoma (MTC). Currently, there is growing interest for PET tracers in MTC such as: 18F-FDG (reflecting glucose metabolism), 18F-DOPA (reflecting amine decarboxylation), 68Ga-somatostatin analogues (reflecting somatostatin receptors expression)
Conference:
Category: Basic
Presenting Author: Dr. Giorgio Treglia